Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

Roberta Nuccorini, Sara Pasquina Pascale, Sabrina Coluzzi, Andrea Bacigalupo, Attilio Olivieri, Michele Cimminiello, Paolo Corradini, Nicola Mordini, Roberta Fedele, Carmine Selleri, Francesco Onida, Francesca Patriarca, Enzo Pavone, Silvia Svegliati, Armando Gabrielli, Paola Bresciani, Sara Pascale, Fabrizio Pane, Antonella Poloni, Jacopo OlivieriPietro Leoni

Risultato della ricerca: Contributo in rivistaArticolo in rivista

59 Citazioni (Scopus)

Abstract

na
Lingua originaleEnglish
pagine (da-a)4111-8-4118
RivistaBlood
Volume122
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal
  • Autoantibodies
  • Benzamides
  • Chronic Disease
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Imatinib Mesylate
  • Lymphoproliferative Disorders
  • Male
  • Middle Aged
  • Monitoring, Physiologic
  • Myeloproliferative Disorders
  • Piperazines
  • Prednisolone
  • Prospective Studies
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptors, Platelet-Derived Growth Factor
  • Severity of Illness Index
  • Survival Rate
  • Time Factors

Fingerprint Entra nei temi di ricerca di 'Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD'. Insieme formano una fingerprint unica.

Cita questo